# VERU catalysts: VERU INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/veru/catalysts

> VERU INC. (VERU) has 6 upcoming catalysts. The next is the Zepbound (tirzepatide) interim data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | VERU INC. |
| Ticker | VERU (Nasdaq) |
| SEC CIK | 863894 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/veru |

## Cash runway

Cash $23.9M as of 2026-06-30; quarterly burn $5.5M; about 13.1 months of runway at that rate (XBRL company facts, accession 0001437749-26-026664).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 19, 2023 | [ENTADFI® (finasteride-tadalafil) FDA approval](https://sec-api.dev/pdufa/finasteride-tadalafil) | VERU |  | completed, approved | "On April 19, 2023, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") to sell substantially all of the assets related to ENTADFI® (finasteride and tadalafil) capsules for oral use, a new treatment for benign prostatic hyperplasia that was approved by the FDA in December 2021, with ONCO." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/863894/000143774926026664/veru20260630_10q.htm)) |
| Jan 2025 | [Sabizabulin topline data readout](https://sec-api.dev/pdufa/sabizabulin) | VERU |  | scheduled | "We are expecting topline clinical results for this study in January 2025."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000143774925000208/ex_761785.htm)) |
| Jan 2025 | [VERU INC. topline data readout](https://sec-api.dev/companies/veru/catalysts) | VERU |  | delayed | "In April 2024 the Company announced that it had enrolled its first patients in the Phase 2b QUALITY clinical study, and in August 2024, the Company completed enrollment of 168 subjects in 14 clinical sites in the U.S. with the topline clinical results from the trial expected in January 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/863894/000143774924037576/veru20240930_10k.htm)) |
| January 27, 2025 | [VERU INC. topline data readout](https://sec-api.dev/companies/veru/catalysts) | VERU |  | completed, positive | "On January 27, 2025, the Company announced positive topline results from the Phase 2b QUALITY clinical study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/863894/000143774925015330/veru20250331_10q.htm)) |
| January 27, 2025 | [Enobosarm topline data readout](https://sec-api.dev/pdufa/enobosarm) | VERU |  | completed, positive | "On January 27, 2025, the Company announced positive topline results from the Phase 2b QUALITY clinical study which is a multicenter, double-blind, placebo-controlled, randomized, dose-finding QUALITY clinical trial designed to evaluate the safety and efficacy of enobosarm 3mg, enobosarm 6mg, or placebo as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight older (>60 years of age) patients receiving semaglutide (Wegovy)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312525025576/d935703dex991.htm)) |
| January 27, 2025 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | VERU |  | completed, positive | "On January 27, 2025, the Company announced positive topline results from the Phase 2b QUALITY clinical study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/863894/000143774925003734/veru20241231_10q.htm)) |
| February 13, 2025 | [VERU INC. earnings report](https://sec-api.dev/companies/veru/catalysts) | VERU |  | completed | "Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312525025576/d935703dex991.htm)) |
| Q2 2025 | [Sabizabulin topline data readout](https://sec-api.dev/pdufa/sabizabulin) | VERU |  | scheduled | "The topline results of the separate blinded Phase 2b extension clinical study are expected in calendar Q2 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000143774925000208/ex_761785.htm)) |
| May 8, 2025 | [VERU INC. earnings report](https://sec-api.dev/companies/veru/catalysts) | VERU |  | completed | "Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312525115453/d937042dex991.htm)) |
| May 28, 2025 | [Enobosarm topline data readout](https://sec-api.dev/pdufa/enobosarm) | VERU |  | completed, positive | "On May 28, 2025, we announced positive topline safety results for the Phase 2b QUALITY clinical study that showed the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/863894/000143774925026072/veru20250630_10q.htm)) |
| May 28, 2025 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | VERU |  | completed, positive | "On May 28, 2025, we announced positive topline safety results for the Phase 2b QUALITY clinical study portion during the 16 weeks of active weight loss that showed the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/863894/000143774926026664/veru20260630_10q.htm)) |
| August 12, 2025 | [VERU INC. earnings report](https://sec-api.dev/companies/veru/catalysts) | VERU |  | completed | "Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312525178463/d59822dex991.htm)) |
| December 17, 2025 | [VERU INC. earnings report](https://sec-api.dev/companies/veru/catalysts) | VERU |  | completed | "Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312525321663/d55858dex991.htm)) |
| February 11, 2026 | [VERU INC. earnings report](https://sec-api.dev/companies/veru/catalysts) | VERU |  | completed | "Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312526045527/d218771dex991.htm)) |
| May 13, 2026 | [VERU INC. earnings report](https://sec-api.dev/companies/veru/catalysts) | VERU |  | completed | "Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312526220569/d114190dex991.htm)) |
| August 10, 2026 | [VERU INC. earnings report](https://sec-api.dev/companies/veru/catalysts) | VERU |  | completed | "Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312526341187/d123580dex991.htm)) |
| Q1 2027 | [Zepbound (tirzepatide) interim data readout](https://sec-api.dev/pdufa/tirzepatide) | VERU |  | scheduled | "The Phase 2b PLATEAU clinical study is expected to begin in the first quarter of calendar 2026 and an interim analysis is planned for the first quarter of calendar 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312526045527/d218771dex991.htm)) |
| Q1 2027 | [VERU INC. interim data readout](https://sec-api.dev/companies/veru/catalysts) | VERU |  | scheduled | "— Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027 —" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312526341187/d123580dex991.htm)) |
| Q1 2027 | [Wegovy (semaglutide) interim data readout](https://sec-api.dev/pdufa/semaglutide) | VERU |  | scheduled | "—Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027—" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312526220569/d114190dex991.htm)) |
| Q1 2027 | [Enobosarm interim data readout](https://sec-api.dev/pdufa/enobosarm) | VERU |  | scheduled | "GLP-1 RA fully on track - Phase 2b PLATEAU clinical trial interim analysis near term milestone calendar Q1 2027, clinical supply agreement with Novo Nordisk, strong IP protection with newly issued patent for enobosarm with GLP-1 RA until late 2044—" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312526384430/d543118dex991.htm)) |
| October 2027 | [Enobosarm primary completion](https://sec-api.dev/pdufa/enobosarm) | VERU | Obesity & Overweight; Mobility Disability; HOMA-IR | scheduled | "NCT07446998 (Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Veru Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07446998)) |
| Oct 2027 to Jan 2028 | [Enobosarm topline data readout](https://sec-api.dev/pdufa/enobosarm) | VERU | Obesity & Overweight; Mobility Disability; HOMA-IR | scheduled | "NCT07446998 (Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Veru Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07446998)) |

## Drugs

- [Enobosarm](https://sec-api.dev/pdufa/enobosarm): Obesity & Overweight
- [ENTADFI® (finasteride-tadalafil)](https://sec-api.dev/pdufa/finasteride-tadalafil): 
- [Sabizabulin](https://sec-api.dev/pdufa/sabizabulin): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/veru/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VERU catalysts: VERU INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/veru/catalysts

```bibtex
@misc{secapidev_companies_veru_catalysts_20261116,
  title        = {VERU catalysts: VERU INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/veru/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_veru_catalysts_20261116","title":"VERU catalysts: VERU INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/veru/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
